Acute Ischemic Stroke - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 102 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Acute Ischemic Stroke - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Acute Ischemic Stroke - Pipeline Review, H2 2014', provides an overview of the Acute Ischemic Stroke's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Ischemic Stroke
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acute Ischemic Stroke and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acute Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Ischemic Stroke pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Ischemic Stroke
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Ischemic Stroke pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Acute Ischemic Stroke Overview 8
Therapeutics Development 9
Pipeline Products for Acute Ischemic Stroke - Overview 9
Pipeline Products for Acute Ischemic Stroke - Comparative Analysis 10
Acute Ischemic Stroke - Therapeutics under Development by Companies 11
Acute Ischemic Stroke - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Acute Ischemic Stroke - Products under Development by Companies 16
Acute Ischemic Stroke - Companies Involved in Therapeutics Development 17
Biogen Idec Inc. 17
AstraZeneca PLC 18
Daiichi Sankyo Company, Limited 19
Grifols, S.A. 20
Reliance Life Sciences Pvt. Ltd. 21
H. Lundbeck A/S 22
Mitsubishi Tanabe Pharma Corporation 23
Oxygen Biotherapeutics, Inc. 24
PhytoHealth Corporation 25
Simcere Pharmaceutical Group 26
D-Pharm Ltd. 27
Remedy Pharmaceuticals, Inc. 28
Stemedica Cell Technologies, Inc. 29
Glucox Biotech AB 30
Pharmicell Co., Ltd. 31
Genervon Biopharmaceuticals, LLC 32
Acute Ischemic Stroke - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
desmoteplase - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ticagrelor - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Cerecellgram-Stroke - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
natalizumab - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
SIM-071201 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
GM-602 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
glyburide - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Mesenchymal Stem Cells - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
THR-18 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
3K3A-APC - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
PHN-014 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
RTPR-004 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Human Plasmin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
MP-124 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
TS-01 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
DS-1040 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Oxycyte - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Recombinant Plasmin - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
HBN-1 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Human Ghrelin - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Acute Ischemic Stroke - Recent Pipeline Updates 75
Acute Ischemic Stroke - Dormant Projects 91
Acute Ischemic Stroke - Discontinued Products 92
Acute Ischemic Stroke - Product Development Milestones 93
Featured News & Press Releases 93
Aug 19, 2014: US Department of Justice Closes Investigation into PLATO Clinical Trial for BRILINTA 93
Jun 03, 2014: Thrasos Presents Preclinical Data Demonstrating THR-184 Prevents Loss of Kidney Function Following Acute Ischemic Injury 93
Jun 02, 2014: D-Pharm Reports Completion of the Second Dose Tier in its Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated with the Thrombolytic Drug tPA 94
Apr 22, 2014: ZZ Biotech Announces Phase 2 Trial with 3K3A-APC in Stroke; Funds Will Be Provided by NIH and Broadview Ventures 94
Mar 04, 2014: D-Pharm reports the successful interim analysis of its Phase 2 clinical study of THR-18 in acute stroke patients 96
Jan 21, 2014: D-Pharm completes recruitment of patients into the first dosage tier of its Phase 2 study with THR-18 in acute stroke patients treated with tPA 96
Jan 08, 2014: D-Pharm receives grant to support the development of its Phase 2 product, THR-18 97
Dec 05, 2013: AstraZeneca announces initiation of two additional global studies for BRILINTA 97
Oct 30, 2013: D-Pharm Granted Patent in US and China for its Phase II Product THR-18 99
Oct 16, 2013: D-Pharm Commences Phase 2 Study with THR-18 In Stroke Patients Treated with Tissue Plasminogen Activator 99
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 102
Disclaimer 102

List of Tables
Number of Products under Development for Acute Ischemic Stroke, H2 2014 9
Number of Products under Development for Acute Ischemic Stroke - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Acute Ischemic Stroke - Pipeline by Biogen Idec Inc., H2 2014 17
Acute Ischemic Stroke - Pipeline by AstraZeneca PLC, H2 2014 18
Acute Ischemic Stroke - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 19
Acute Ischemic Stroke - Pipeline by Grifols, S.A., H2 2014 20
Acute Ischemic Stroke - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2014 21
Acute Ischemic Stroke - Pipeline by H. Lundbeck A/S, H2 2014 22
Acute Ischemic Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 23
Acute Ischemic Stroke - Pipeline by Oxygen Biotherapeutics, Inc., H2 2014 24
Acute Ischemic Stroke - Pipeline by PhytoHealth Corporation, H2 2014 25
Acute Ischemic Stroke - Pipeline by Simcere Pharmaceutical Group, H2 2014 26
Acute Ischemic Stroke - Pipeline by D-Pharm Ltd., H2 2014 27
Acute Ischemic Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H2 2014 28
Acute Ischemic Stroke - Pipeline by Stemedica Cell Technologies, Inc., H2 2014 29
Acute Ischemic Stroke - Pipeline by Glucox Biotech AB, H2 2014 30
Acute Ischemic Stroke - Pipeline by Pharmicell Co., Ltd., H2 2014 31
Acute Ischemic Stroke - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2014 32
Assessment by Monotherapy Products, H2 2014 33
Number of Products by Stage and Target, H2 2014 35
Number of Products by Stage and Mechanism of Action, H2 2014 38
Number of Products by Stage and Route of Administration, H2 2014 40
Number of Products by Stage and Molecule Type, H2 2014 42
Acute Ischemic Stroke Therapeutics - Recent Pipeline Updates, H2 2014 75
Acute Ischemic Stroke - Dormant Projects, H2 2014 91
Acute Ischemic Stroke - Discontinued Products, H2 2014 92